Lastly, the expression of Mcl-1, a prominent target in cancer therapy [1,53,54,55], a member of the anti-apoptotic BCL-2 family, and a predictor of poor prognosis and disease recurrence in AML [56], was impacted by the inhibitor combination. This evidence concerns the gene BCL2 and acute myeloid leukemia.